XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Stock Overview
NASDAQ:XOMAP - US98419J3059
XOMAP Key Statistics, Chart & Performance
The current stock price of XOMAP is 26.76 USD. In the past month the price increased by 4.33%. In the past year, price increased by 4.57%.
XOMAP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.07 | 375.50B | ||
| AMGN | AMGEN INC | 13.01 | 152.70B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.99 | 40.63B | ||
| INSM | INSMED INC | N/A | 30.67B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
| NTRA | NATERA INC | N/A | 23.06B | ||
| BIIB | BIOGEN INC | 8.79 | 20.62B |
Related stock screener links
About XOMAP
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The firm also acquires milestone and royalty revenue streams on late-stage or commercial assets.
Company Info
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
2200 Powell Street, Suite 310
Emeryville CALIFORNIA US
Employees: 13
Phone: 15102047239
XOMA ROYALTY CORP - XOMA 8 5/8 PERP / XOMAP FAQ
What is the stock price of XOMA ROYALTY CORP - XOMA 8 5/8 PERP today?
The current stock price of XOMAP is 26.76 USD. The price increased by 0.41% in the last trading session.
What is the ticker symbol for XOMA ROYALTY CORP - XOMA 8 5/8 PERP stock?
The exchange symbol of XOMA ROYALTY CORP - XOMA 8 5/8 PERP is XOMAP and it is listed on the Nasdaq exchange.
On which exchange is XOMAP stock listed?
XOMAP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for XOMA ROYALTY CORP - XOMA 8 5/8 PERP stock?
10 analysts have analysed XOMAP and the average price target is 52.65 USD. This implies a price increase of 96.75% is expected in the next year compared to the current price of 26.76. Check the XOMA ROYALTY CORP - XOMA 8 5/8 PERP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is XOMA ROYALTY CORP - XOMA 8 5/8 PERP worth?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a market capitalization of 323.53M USD. This makes XOMAP a Small Cap stock.
How many employees does XOMA ROYALTY CORP - XOMA 8 5/8 PERP have?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) currently has 13 employees.
What are the support and resistance levels for XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a support level at 26.5 and a resistance level at 26.77. Check the full technical report for a detailed analysis of XOMAP support and resistance levels.
Is XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) expected to grow?
The Revenue of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is expected to grow by 78.53% in the next year. Check the estimates tab for more information on the XOMAP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XOMAP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XOMAP, evaluating the profitability, health, valuation and growth aspects
- XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Sales and EPS estimates to see what analysts future expectations are.
- XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Insider and Institutional Ownership to learn about the owners and their transactions.
- XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Stock Chart to make your own analysis
- XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Latest news and press-releases to stay up to date.
Does XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock pay dividends?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a dividend yield of 8.06%. The yearly dividend amount is currently 0.47. Check the full fundamental report for a detailed analysis of XOMAP dividend history, reliability and sustainability.
When does XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) report earnings?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) will report earnings on 2025-11-05.
What is the Price/Earnings (PE) ratio of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP)?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).
What is the Short Interest ratio of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock?
The outstanding short interest for XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is 0% of its float. Check the ownership tab for more information on the XOMAP short interest.
XOMAP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to XOMAP. When comparing the yearly performance of all stocks, XOMAP turns out to be only a medium performer in the overall market: it outperformed 45.85% of all stocks.
XOMAP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XOMAP. XOMAP has a medium profitability rating, but doesn't score so well on its financial health evaluation.
XOMAP Financial Highlights
Over the last trailing twelve months XOMAP reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by -38.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| Debt/Equity | 1.11 |
XOMAP Forecast & Estimates
10 analysts have analysed XOMAP and the average price target is 52.65 USD. This implies a price increase of 96.75% is expected in the next year compared to the current price of 26.76.
For the next year, analysts expect an EPS growth of 117.66% and a revenue growth 78.53% for XOMAP